|
Post by mnkdfann on Jan 4, 2020 19:56:50 GMT -5
Wow ... and I thought the pps went up a penny yesterday. But, that's mytakeonit Yahoo Finance shows it down 3 cents, not up. That's all I know.
|
|
|
Post by letitride on Jan 4, 2020 20:33:51 GMT -5
I have a lot of lost time to make up for so just keep feeding me those 40 million extra shares and I promise I will not be giving them back anytime soon.
|
|
|
Post by ktim on Jan 4, 2020 21:18:46 GMT -5
I have a lot of lost time to make up for so just keep feeding me those 40 million extra shares and I promise I will not be giving them back anytime soon. Open short interest basically is the same as it was 3 months ago, so shorts aren't being a source of extra shares recently. I did sell shares in Dec to capture tax loss. You might have been buying some of those, and if so, thanks.
|
|
|
Post by letitride on Jan 4, 2020 21:39:24 GMT -5
You're welcome
|
|
|
Post by lennymnkd on Jan 20, 2020 11:24:01 GMT -5
3 Top-Notch “Strong Buy” Stocks Under $3
TipRanksJanuary 20, 2020 Mnkd first one on list 🤔fwiw. On yahoo
|
|
|
Post by brentie on Jan 20, 2020 11:30:19 GMT -5
|
|
|
Post by sportsrancho on Jan 20, 2020 12:24:35 GMT -5
Let’s start off with the cheapest stock on our list, MannKind Corporation. Shares of the small-cap biotech are currently selling for $1.51. The diabetes-focused company has a market cap of $312 million, but looking back to the mid 2010’s, MannKind was worth almost $4 billion. So, what happened since then?
Bad financial practices combined with underwhelming sales have seen the company lose favor with investors. However, according to Oppenheimer’s Steven Lichtman, MannKind has been steering itself to safety over the last couple of years.
Lichtman initiated coverage of MannKind with an Outperform rating and set a price target of $2.50. The figure suggests a possible gain of 66% over the coming months. (To watch Lichtman’s track record, click here)
MNKD has one approved FDA treatment on the market: Afrezza. It’s a device which consists of a dry powder formulation of human insulin that is delivered through a portable inhaler. The superfast mealtime insulin’s goal is to improve post-meal glucose control without increasing the risk of hypoglycemia. Although it’s popular with the few who use it, part of its problem has been the lack of insurance for its users. The company has been working with payers and, additionally, new data has helped prescription growth. According to Lichtman, shifting mealtime insulin users away from “tough competitors" towards Afrezza remains key for its success.
Lichtman said, “MNKD management has taken steps over the past couple of years to accelerate Afrezza (insulin delivery) sales and diversify using its core Technosphere drug delivery platform. Successes have included continued solid data behind Afrezza and a new partnership with United Therapeutics (UTHR) using Technosphere in UTHR's PAH drugs... While we have not yet seen an inflection in new prescriptions, prescriptions have been steadily increasing, the pipeline around MNKD’s core Technosphere technology has increased and the company's efforts to restructure cash commitments have improved the risk/reward on the shares, in our view.”
The Street is currently quiet when it comes to MNKD’s prospects. Those that have been taking note, though, remain bullish on its future. 3 Buy ratings add up to a Strong Buy consensus rating. The average price target is identical to Lichtman’s, $2.50, and therefore also indicates upside potential of 66%. (See MannKind stock analysis on TipRanks)
|
|
|
Post by sportsrancho on Jan 20, 2020 13:03:16 GMT -5
|
|